Trials on Septic Shock

Trials on Septic Shock

• CTIN816B12202 - A multicenter, randomized, double-blind, placebocontrolled, four-arm, parallel-group, dose-finding phase 2b study to investigate the safety and efficacy of TIN816 via a single intravenous infusion in the treatment of participants with sepsis-associated acute kidney injury (SA-AKI) - ONGOING - Sponsor: Novartis

• ENX-CL-02-002 - A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients - ENROLMENT CLOSED - Sponsor: Enlivex Therapeutics R&D Ltd.

• CTIN816B12201 - A multicenter, participant and investigator-blinded, randomized, placebo-controlled Phase 2a study to investigate the pharmacokinetics, pharmacodynamics, safety and tolerability of TIN816 in the treatment of patients with sepsis-associated acute kidney injury - CLOSED - Sponsor: Novartis

• ASTONISH - Efficacy, Safety and Tolerability of Nangibotide in Patients with Septic Shock. A Randomized, Double-blind, Placebo Controlled Dose Selection Study. The ASTONISH Study - CLOSED - Sponsor: INOTREM -  https://www.thelancet.com/jou...

• ESSENTIAL - Efficacy and Safety Study Exploring Nangibotide Treatment in COVID-19 pAtients with ventiLatory support. A randomized, double-blind, placebo-controlled study with adaptive features. The ESSENTIAL Study - CLOSED - Sponsor: INOTREM - https://www.thelancet.com/jour...

• REVIVAL - A Randomized, Double-Blind, Placebo-Controlled, Two-Arm Parallel-Group, Multi-Center Phase 3 Pivotal Trial to Investigate the Efficacy and Safety of Recombinant Human Alkaline Phosphatase for Treatment of Patients with Sepsis-Associated Acute Kidney Injury - CLOSED - Sponsor: AM-Pharma B.V